New Ghrelin Variant Linked to Breast Cancer
Author Information
Author(s): Manuel D. Gahete, José Córdoba-Chacón, Marta Hergueta-Redondo, Antonio J. Martínez-Fuentes, Rhonda D. Kineman, Gema Moreno-Bueno, Raúl M. Luque, Justo P. Castaño
Primary Institution: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Córdoba
Hypothesis
The study investigates the expression and potential role of a novel human ghrelin variant (In1-ghrelin) in breast cancer.
Conclusion
The In1-ghrelin variant is overexpressed in breast cancer tissues and may play a significant role in tumor proliferation.
Supporting Evidence
- In1-ghrelin variant expression was found to be 8-fold higher in breast cancer samples compared to normal tissue.
- Expression levels of In1-ghrelin variant were positively correlated with ghrelin-O-acyltransferase (GOAT) levels.
- Overexpression of In1-ghrelin variant increased the proliferation rate of MDA-MB-231 breast cancer cells.
Takeaway
Researchers found a new version of a hormone called ghrelin that is much more common in breast cancer than in normal breast tissue, which might help cancer cells grow.
Methodology
The study used quantitative real-time PCR to measure expression levels of In1-ghrelin in breast cancer and normal tissue samples.
Potential Biases
Potential bias may arise from the use of a commercial RNA panel and the classification of breast cancer samples.
Limitations
The study is limited by the small sample size of normal breast tissue and the lack of functional assays to confirm the role of In1-ghrelin in cancer.
Participant Demographics
The mean patient age at surgery was 53 years, with a range from 27 to 87 years.
Statistical Information
P-Value
0.0042
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website